The new fluoride? FDA greenlights rapamycin oral health trial [Longevity.Technology]

In the News
Written By Teddy Otero

Longevity.Technology wrote about Optispan’s collaboration with the RAPID trial to assess the efficacy of rapamycin in treating periodontal disease.

Teddy Otero
Previous

Optimizing healthspan, empowering longevity clinics and exploring biological age. [Longevity.Technology]
Next

Optispan CEO Matt Kaeberlein Named "Healthcare Innovator of the Year" by Puget Sound Business Journal